Vavricka, Stephan R <br/><br/>
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).  [electronic resource] 

 -  Inflammatory bowel diseases  Aug 2012 
 - 1523-30 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1536-4844 
<br/><br/><label>Standard No.: </label>10.1002/ibd.21888  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anti-Inflammatory Agents--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Certolizumab Pegol<br/>Crohn Disease--drug therapy<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--administration & dosage<br/>Immunosuppressive Agents--therapeutic use<br/>Infliximab<br/>Infusions, Intravenous<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Patient Preference<br/>Polyethylene Glycols--administration & dosage<br/>Prognosis<br/>Prospective Studies<br/>Surveys and Questionnaires<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Young Adult